GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intravenous Infusions Ltd (XGHA:IIL) » Definitions » Net Current Asset Value

Intravenous Infusions (XGHA:IIL) Net Current Asset Value : GHS0.00 (As of . 20)


View and export this data going back to 2015. Start your Free Trial

What is Intravenous Infusions Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Intravenous Infusions's net current asset value per share for the quarter that ended in . 20 was GHS0.00.

The historical rank and industry rank for Intravenous Infusions's Net Current Asset Value or its related term are showing as below:

XGHA:IIL's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.03
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Intravenous Infusions Net Current Asset Value Historical Data

The historical data trend for Intravenous Infusions's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intravenous Infusions Net Current Asset Value Chart

Intravenous Infusions Annual Data
Trend
Net Current Asset Value

Intravenous Infusions Semi-Annual Data
Net Current Asset Value

Competitive Comparison of Intravenous Infusions's Net Current Asset Value

For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intravenous Infusions's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Intravenous Infusions's Price-to-Net-Current-Asset-Value falls into.



Intravenous Infusions Net Current Asset Value Calculation

Intravenous Infusions's Net Current Asset Value (NCAV) per share for the fiscal year that ended in . 20 is calculated as

Net Current Asset Value Per Share(A: . 20 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(-N/A--)/0
=N/A

Intravenous Infusions's Net Current Asset Value (NCAV) per share for the quarter that ended in . 20 is calculated as

Net Current Asset Value Per Share(Q: . 20 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(-N/A--)/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intravenous Infusions  (XGHA:IIL) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Intravenous Infusions Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Intravenous Infusions's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Intravenous Infusions (XGHA:IIL) Business Description

Traded in Other Exchanges
N/A
Address
Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.